Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes
Language English Country Great Britain, England Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
- Keywords
- HER2, androgen receptor, basal cytokeratins, basal-like phenotype, molecular subtypes, salivary duct carcinoma,
- MeSH
- Receptors, Androgen analysis biosynthesis genetics MeSH
- Tissue Array Analysis MeSH
- Adult MeSH
- Carcinoma, Ductal classification genetics pathology MeSH
- Phenotype MeSH
- In Situ Hybridization MeSH
- Immunohistochemistry MeSH
- Carcinoma in Situ classification genetics pathology MeSH
- Carcinoma classification genetics pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Biomarkers, Tumor analysis MeSH
- Salivary Gland Neoplasms classification genetics pathology MeSH
- Receptor, ErbB-2 analysis biosynthesis genetics MeSH
- Oligonucleotide Array Sequence Analysis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Transcriptome MeSH
- Salivary Ducts pathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Receptors, Androgen MeSH
- AR protein, human MeSH Browser
- ERBB2 protein, human MeSH Browser
- Biomarkers, Tumor MeSH
- Receptor, ErbB-2 MeSH
AIMS: The aim of this study was to devise a molecular classification for salivary duct carcinomas (SDCs) based on the similarities between SDCs and breast carcinomas and on characteristics of the microarray-based gene expression profiling-defined molecular subtypes of breast cancer. METHODS AND RESULTS: Forty-two pure salivary duct carcinomas, 35 of which contained an in-situ component as defined by histological review and/or immunohistochemical analysis, were stained with antibodies for oestrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR) and cytokeratin (CK) 5/6. Based on these markers, tumours were classified into HER2, luminal androgen receptor-positive, basal-like, luminal and indeterminate phenotype. Analysis revealed that 16.7%, 69%, 4.8%, 9.5% and 0% were of HER2, luminal androgen receptor-positive, basal-like, indeterminate and luminal phenotype, respectively. The in-situ and invasive components displayed the same molecular subtype in all but one case. CONCLUSION: Salivary duct carcinomas can be classified into molecular subgroups approximately equivalent to those in the breast. We also report on the existence of a subgroup of bona fide pure salivary duct carcinomas that have a 'basal-like' phenotype. Understanding the phenotypic complexity of SDCs may help to expedite the identification of novel therapeutic targets for these aggressive tumours.
References provided by Crossref.org
Development of head and neck pathology in Europe
